Semaglutide (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Once weekly sub-Q on the Wegovy ladder shown above, at the same time each week. The seven day half life is the longest in the incretin class and produces a smoother plasma curve than tirzepatide at five days or retatrutide at six; steady state takes 4 to 5 weeks at any new dose, and residual drug persists 5 to 7 weeks after the last injection. Each step is held at least 4 weeks before increasing, which is what keeps GI symptoms from stacking on top of a dose whose full effect has not landed yet. The stop short logic is the part that separates semaglutide from the rest of the class: STEP-2 randomized 1.0 mg against 2.4 mg head to head over 68 weeks and found 1.0 mg retains about 73% of the weight loss effect at much lower GI cost, so most users find their effective dose somewhere between 0.5 and 1.0 mg and never need the top rung. The one exception is cardiovascular protection, since the SELECT 20% MACE reduction was measured at 2.4 mg and dropping below that for a CV indication is extrapolation rather than measured evidence. Split dose schedules are rarely needed here, because the seven day half life already smooths the curve. Sites are rotated systematically across abdomen, thighs, and upper arms to avoid lipohypertrophy, and every dose in this protocol fits inside a single U-100 syringe.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 4: 0.25 mg, 5 units, for GI adaptation only. Appetite suppression is usually noticeable within 1 to 2 weeks, but this step is explicitly non therapeutic and holding at it indefinitely delivers adaptation rather than STEP-1 or STEP-2 outcomes.
• Weeks 4 to 8: steady weight loss begins around week 4 while GI side effects peak, with nausea at 44% in STEP-1; most symptoms fade over 2 to 4 weeks at a given step.
• Weeks 8 to 16: the ladder reaches 0.5 mg and then 1.0 mg, the stop short band where most users settle. Steady state arrives 4 to 5 weeks into each new dose.
• Months 12 to 16: 10 to 15% total weight loss at effective doses, with STEP-5 confirming durable maintenance out to 104 weeks at 2.4 mg.
• After the last dose: residual drug persists 5 to 7 weeks, and regain follows in most users within 12 months. A gradual taper is preferred over abrupt cessation, with maintenance at 0.25 to 0.5 mg alongside resistance training and protein targets to buy time for habits to hold.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg on a U-100 insulin syringe.
5. Ladder conversions at 5 mg/mL: 0.25 mg = 5 units; 0.5 mg = 10 units; 1.0 mg = 20 units; 1.7 mg = 34 units; 2.4 mg = 48 units. Every dose in this protocol fits one U-100 syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C (-4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake.
• Keep reconstituted vials out of the refrigerator door, where temperature swings are largest, and label each one with date and concentration so draw volumes are never guessed.

Supplies Needed

Planning math is based on a 16 week titration from 0.25 mg up to 1.0 mg weekly maintenance, the stop short path, at one injection per week.

Peptide Vials (Semaglutide, 10 mg vial):

• That 16 week course totals about 9 mg, which is about 1 vial at 10 mg each; a 20 week full titration to 2.4 mg totals about 26 mg, or about 3 vials. Ongoing 1.0 mg weekly maintenance runs 4 mg per month, about 1 vial every 2.5 months, while 2.4 mg weekly maintenance runs about 10 mg per month, about 1 vial per month.

Insulin Syringes (U-100):

• Per week: 1 U-100 syringe, 50 unit barrel preferred, since every dose through 2.4 mg fits in one.
• Full cycle: 16 syringes across the 16 week titration, and 52 for a year of weekly maintenance.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg vial takes 2.0 mL, so one 10 mL bottle covers about 5 vials: 1 bottle for the titration course and 2 to 3 bottles for a year of weekly maintenance.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the skin.
• Full cycle: about 32 swabs across the 16 week titration and about 104 for a year of weekly maintenance, which one 100 count box covers.

Important Notes

Practical considerations for consistency and safety.

• Stop short is uniquely evidence backed here. STEP-2 compared 1.0 mg against 2.4 mg directly over 68 weeks in T2D with obesity: 1.0 mg produced about 7.0% weight loss and 2.4 mg about 9.6%, so 1.0 mg retains about 73% of the effect. Most users find their effective dose between 0.5 and 1.0 mg and not everyone needs the 2.4 mg top. The floor is a different matter: 0.25 mg is not a maintenance dose, it is the 4 week GI adaptation step, and sitting on it indefinitely delivers adaptation rather than trial outcomes.
• The exception to stop short is cardiovascular protection. The SELECT 20% MACE reduction was measured at 2.4 mg in obesity with established CVD and without diabetes. If CV outcomes are the primary goal, dropping below 2.4 mg is extrapolation, not measured evidence. The same applies to MASH, where the ESSENCE histologic result was measured at 2.4 mg.
• Body weight shifts plasma exposure, which is unique to semaglutide in this class and is not true of tirzepatide or retatrutide. Against the 85 kg reference, a 55 kg user sees about 40% higher exposure, 70 kg about 15% higher, 100 kg about 10% lower, and 127 kg about 27% lower. Trials enrolled a mean BMI of 30 to 35, so lighter users may respond at lower mg than the label suggests and tolerate them worse, while heavier users may need to step further to match trial pharmacology.
• Oral to sub-Q equivalence is widely miscalculated. 14 mg Rybelsus daily is roughly equal to 0.5 mg sub-Q weekly, not 1.0 mg, and switching at the wrong ratio doubles exposure overnight. Rybelsus also carries the strictest fasting requirement in the class: empty stomach, 30 minutes before any food or drink, with no more than 4 oz of plain water, because the SNAC absorption enhancer works in a narrow window.
• Above 2.4 mg is uncharacterized. Every trial capped there, the dose response saturates near it, and no prospective efficacy or safety data exists beyond it. Gallbladder risk is already elevated at about 2.6 times the odds of cholelithiasis vs placebo, and severe right sided abdominal pain after meals warrants imaging. Contraindications named in the source material: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, history of pancreatitis, pregnancy or breastfeeding, and severe gastroparesis.
• Regulatory Note: semaglutide is FDA approved as Ozempic for type 2 diabetes, Wegovy for obesity, and Rybelsus for oral type 2 diabetes. Research grade compounded vials at 10 mg are containers for weeks of sub 2.4 mg weekly dosing, not a license to exceed the trial safety envelope. On cost, brand runs $900 to $1700 per month without insurance and compounded runs $200 to $500 per month from 503A or 503B pharmacies, where 503B carries the stricter oversight; certificates of analysis are worth asking for either way. WADA status is not addressed in the source material.

How This Works

Semaglutide is a modified GLP-1 with a fatty acid side chain that binds albumin, extending half life to about 7 days, the longest in the incretin class. At the GLP-1 receptor it amplifies and prolongs the post meal signal that native GLP-1 provides only briefly, and three downstream actions follow. First, appetite and fullness: at brainstem and hypothalamic GLP-1 receptors it quiets hunger and food seeking signals, increases meal satiation, and reduces intrusive food thoughts. Second, gastric emptying: food leaves the stomach more gradually, which extends fullness and smooths post meal glucose excursions. Third, pancreas and liver: insulin release becomes glucose dependent, backing off when glucose is normal and so carrying less hypoglycemia risk than sulfonylureas, alongside reduced glucagon and improved insulin sensitivity. What semaglutide does not do matters just as much. There is no GIP receptor signal into adipose tissue, which tirzepatide has, and no glucagon receptor engagement, which retatrutide has. That single receptor design is why its body composition in non diabetic obesity is less fat selective, roughly 62:38 fat to lean against tirzepatide at about 75:25, and why its absolute weight loss magnitude sits below the dual and triple agonists. It is also why the evidence led use cases are not raw magnitude at all: they are cardiovascular protection, MASH histologic resolution, kidney outcomes in type 2 diabetes with CKD, chronic exposure safety characterization, and the only oral GLP-1 formulation on the market. The seven day half life produces a smoother plasma curve than tirzepatide at five days or retatrutide at six, reaching steady state in 4 to 5 weeks at any new dose and leaving residual drug for 5 to 7 weeks after discontinuation.

Benefits & Side Effects

Observations from the published record.

• Full dose weight loss anchor: STEP-1 (Wilding 2021) reported about 15% mean weight loss over 68 weeks at 2.4 mg in non diabetic obesity, with about half of participants reaching 15% or more and about a third reaching 20% or more. STEP-5 extended that to 104 weeks and confirmed durable maintenance.
• Stop short and lower dose anchors: STEP-2 (Davies 2021) put 1.0 mg against 2.4 mg head to head over 68 weeks in T2D with obesity, at about 7.0% versus about 9.6%, so 1.0 mg retains roughly 73% of the effect. SUSTAIN-FORTE compared 1.0 mg against 2.0 mg for HbA1c at about 1.9% versus about 2.1%, a 0.2 percentage point gain. SUSTAIN-8 reported about 6% weight loss and 1.5 to 1.9% HbA1c reduction at 1 mg over 52 weeks, and FLOW showed kidney outcome benefit at 1.0 mg over 3.4 years in type 2 diabetes with CKD.
• Outcomes no other GLP-1 has: SELECT (Lincoff 2023) enrolled 17,604 participants for a median 40 months at 2.4 mg in obesity with established CVD and without diabetes and produced a 20% MACE reduction against placebo, the only placebo beaten CV outcome in the class for non diabetics. ESSENCE (Newsome 2025) produced 62.9% MASH histologic resolution against 34.1% on placebo at 72 weeks, the first positive histologic MASH endpoint for any incretin, which makes semaglutide the choice when liver disease is present.
• Where it loses: SURMOUNT-5 (Aronne 2025) is the cleanest head to head, 72 weeks in non diabetic obesity, semaglutide at 13.7% against tirzepatide at 20.2%, a gap of roughly 47% in magnitude that reflects the single receptor limitation. Semaglutide has neither the raw magnitude of the dual and triple agonists, nor the GIP body composition signal, nor glucagon driven liver fat oxidation and metabolic rate defense.
• Body composition and immunogenicity: the STEP-1 DXA substudy put the split at about 62:38 fat to lean in non diabetic obesity, less fat selective than tirzepatide at about 75:25, though the gap narrows in T2D comparisons to roughly 86:14 against 87:13. Immunogenicity is low, with antibodies against the drug in 1 to 3% of users against 51 to 64% for tirzepatide; clinical impact is silent in both so far, but semaglutide has the cleaner profile.
• Side effects scale with dose and GI is the dose limiting reality. In STEP-1: nausea 44%, diarrhea 30%, vomiting 25%, constipation 24%, abdominal pain 20%, worst during the first 4 to 8 weeks of titration and mostly resolving over 2 to 4 weeks as most people adapt. Gallbladder risk is elevated about 2.6 times, pancreatitis is rare at under 1%, and hair thinning is attributed to rapid weight loss rather than a direct drug effect. Slow titration, smaller protein anchored meals, and hydration are the standard countermeasures, with anti emetics if severe. On trajectory, appetite suppression arrives within 1 to 2 weeks, steady weight loss from week 4, and 10 to 15% total loss by 12 to 16 months at effective doses.

Lifestyle Factors

Complementary strategies for best outcomes.

• Protein at 1.0 to 1.2 g per pound of goal weight per day, treated as non negotiable for lean mass preservation, since the 62:38 fat to lean ratio without training and protein discipline is the realistic baseline. Protein first meals matter here too, because early satiety from gastric slowing makes those targets hard to hit; protein goes down before fullness sets in.
• Resistance training 3 to 4x weekly, the primary lever for shifting the body composition ratio. Cardio without strength work accelerates lean mass loss rather than preventing it.
• Eating and hydration pattern during titration: smaller and more frequent meals, since slowed gastric emptying makes large meals uncomfortable; steady hydration and electrolytes, because dehydration worsens nearly every GI side effect; fiber and stool softeners such as magnesium citrate or psyllium for the constipation that hit 24% in STEP-1; fatty, greasy, and spicy trigger foods avoided across the first 4 to 8 weeks; and alcohol kept moderate, since slowed gastric emptying extends its residence in the stomach and tolerance drops sharply.
• Baseline labs and recovery: fasting glucose, HbA1c, lipid panel, liver enzymes (ALT/AST), and a kidney panel, repeated at month 3 and month 6. Sleep of 7 to 9 hours supports the rest of it, since sleep debt amplifies cortisol driven cravings that work against appetite suppression. Optional adjuncts named in the source material are AOD-9604 for a marginal lipolytic effect in stubborn areas once lean, at a modest 2% over placebo, and MOTS-c or NAD+ for mitochondrial support during a deficit.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely.
2. Pinch a fold of skin; insert the needle at a 45 to 90 degree angle into subcutaneous tissue.
3. Do not aspirate when giving a subcutaneous injection.
4. Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle.
5. Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
6. Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection. The abdomen is preferred for most consistent absorption.
7. Dispose of used syringes and needles immediately in a proper FDA-approved sharps container.

References

Source citations for further reading.

1. Wilding JPH, Batterham RL et al. STEP-1: once weekly semaglutide in non diabetic obesity (NEJM, 2021).
2. Davies M, Faerch L et al. STEP-2: 1.0 mg vs 2.4 mg in T2D with obesity (Lancet, 2021).
3. Lincoff AM, Brown-Frandsen K et al. SELECT: 20% MACE reduction in non diabetic obesity with CVD, n=17,604 (NEJM, 2023).
4. Newsome PN et al. ESSENCE: MASH histologic resolution 62.9% vs 34.1% placebo at 72 weeks (NEJM, 2025).
5. Aronne LJ et al. SURMOUNT-5: tirzepatide vs semaglutide in non diabetic obesity, 72 weeks (NEJM, 2025).
6. Dhillon S. Semaglutide pharmacokinetics, seven day half life (Drugs, 2021).